

Hodgkin Lymphoma

Protocol applies to Hodgkin lymphoma involving any organ system except for the gastrointestinal tract.

*Protocol revision date: January 2005
No AJCC/UICC staging system*

Procedures

- **Cytology** (No Accompanying Checklist)
- **Biopsy**
- **Staging Procedure**

Authors

Jonathan Said, MD

Department of Pathology, UCLA School of Medicine, Los Angeles, California

Carolyn Compton, MD, PhD

Department of Pathology, McGill University, Montreal, Quebec, Canada

For the Members of the Cancer Committee, College of American Pathologists

Previous contributors: Judith A. Ferry, MD; Dennis W. Ross, MD, PhD; Annik van den Abbeele, MD; Claire Fung, MD; Nancy L. Harris, MD; Irene Kuter, MD; Peter Mauch, MD

© 2005. College of American Pathologists. All rights reserved.

The College does not permit reproduction of any substantial portion of these protocols without its written authorization. The College hereby authorizes use of these protocols by physicians and other health care providers in reporting on surgical specimens, in teaching, and in carrying out medical research for nonprofit purposes. This authorization does not extend to reproduction or other use of any substantial portion of these protocols for commercial purposes without the written consent of the College.

The College of American Pathologists offers these protocols to assist pathologists in providing clinically useful and relevant information when reporting results of surgical specimen examinations of surgical specimens. The College regards the reporting elements in the "Surgical Pathology Cancer Case Summary (Checklist)" portion of the protocols as essential elements of the pathology report. However, the manner in which these elements are reported is at the discretion of each specific pathologist, taking into account clinician preferences, institutional policies, and individual practice.

The College developed these protocols as an educational tool to assist pathologists in the useful reporting of relevant information. It did not issue the protocols for use in litigation, reimbursement, or other contexts. Nevertheless, the College recognizes that the protocols might be used by hospitals, attorneys, payers, and others. Indeed, effective January 1, 2004, the Commission on Cancer of the American College of Surgeons mandated the use of the checklist elements of the protocols as part of its Cancer Program Standards for Approved Cancer Programs. Therefore, it becomes even more important for pathologists to familiarize themselves with the document. At the same time, the College cautions that use of the protocols other than for their intended educational purpose may involve additional considerations that are beyond the scope of this document.

Summary of Changes to Checklist(s)

Protocol revision date: January 2005

No changes have been made to the data elements of the checklist(s) since the January 2004 protocol revision.

Surgical Pathology Cancer Case Summary (Checklist)

Protocol revision date: January 2005
Applies to non-gastrointestinal Hodgkin lymphoma only
No AJCC/UICC staging system

HODGKIN LYMPHOMA: Biopsy, Staging Procedure

Patient name:

Surgical pathology number:

Note: Check 1 response unless otherwise indicated.

MACROSCOPIC**Specimen Type**

- Lymphadenectomy
 Staging laparotomy
 Other (specify): _____
 Not specified

Tumor Site (check all that apply)

- Lymph node(s), site not specified
 Lymph node(s)
 Specify site(s): _____

 Other tissue(s) or organ(s)
 Specify site(s): _____

Tumor Size (largest single mass)

- Greatest dimension: ___ cm
 *Additional dimensions: ___ x ___ cm
 Specify site: _____
 Cannot be determined (see Comment)

MICROSCOPIC**Histologic Subtype**

- Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)
 Classical Hodgkin lymphoma (CHL), nodular sclerosis Hodgkin lymphoma (NSHL)
 CHL, mixed cellularity Hodgkin lymphoma (MCHL)
 CHL, lymphocyte-rich classical Hodgkin lymphoma (LRCHL)
 CHL, lymphocyte-depleted classical Hodgkin lymphoma (LDHL)
 Other (specify): _____
 Hodgkin lymphoma, subtype cannot be determined

***Histologic Grade (NSHL only)**

- Not applicable
 Grade I
 Grade II

Extent of Pathologically Examined Tumor (check all that apply)

- Involvement of a single lymph node region
 Specify site: _____
 Involvement of multiple lymph node regions
 Specify: _____
 Splenic involvement
 Liver involvement
 Bone marrow involvement
 Other organ involvement
 Specify: _____
 Not specified

Immunophenotyping

- Performed
 *Specify results: _____
 Not performed

***Additional Pathologic Findings (check all that apply)**

- Progressive transformation of germinal centers (PTGC)
 Castleman disease
 Other (specify): _____

***Comment(s)**

* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.